UIC-2018-085 – LPC-EPA, a novel strategy for the prevention and treatment of depression and other neurological diseases

Major Depressive Disorder (MDD) is a leading cause of disability that affects more than 322 million people worldwide. Most drugs in the market are targeted to treat the symptoms of depression, but not the underlying causes. It is important to develop preventive strategies against depression. Studies indicated that Eicosapenteanoic acid (EPA), an omega-3 acid that is generally consumed by eating fish oil or supplement, alleviates depressive symptoms in people with depression. Current form of EPA in fish oil/supplements do not increase EPA level in brain because they can’t cross blood brain barrier efficiently. UIC inventors hypothesized that LPC-EPA can successfully cross blood brain barrier by utilizing blood brain barrier transporter, Mfsd2a that transports lysophosphatidylcholines across the blood brain barrier. The inventors developed lysophosphatidylcholine (LPC) form of EPA. Hyunjin Kim hkim227@otm.uic.edu 312355-7843

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More